FindTrial
Sign In

Comparison between CBC parameters obtained from medical device based on nano-technology and standard method.

To assess potential of automated quantitative blood cell analyzer that combines innovative micro-nano technology and computer vision for blood analysis. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/03/081520
Enrollment
100
Registered
2025-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Epigeneres Biotech Pvt.Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Age: 18-90 years, irrespective of clinical history 2. Subjects who are able to understand and willing to sign the informed consent form (ICF) 3. Subjects who are willing and able to comply with scheduled visit.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Age less than 18 years. 2. Subject suffering from Immune thrombocytopenic purpura (ITP) 3. Subjects on cytotoxic drugs 4. Verified biohazard samples will be excluded

Design outcomes

Primary

MeasureTime frame
1.Assessment of potential of iMOST-L analyzer for the quantitative measurement of blood count (CBC) parameters. 2.Accuracy of the device determined by comparing device generated data with standard blood testing method . 3.Specificity and sensitivity of the iMOST-L analyzer determined by comparing results obtained from peripheral blood and fingertip blood analysis .Timepoint: Baseline—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Mugdha Ghag

Epigeneres Biotech Pvt.Ltd

dr.mugdha@epigeneres.com8698251316

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026